Lanzhou Foci Pharmaceutical Co Ltd
LanZhou Foci Pharmaceutical Co.,Ltd., research and development, production, and sales of traditional chinese medicines and health products in China. The company offers its products in various dosage forms, including pills, tablets, granules, capsules, and gelatin under the MingShan, BaoShu, BaoLu, and Foci brands. It also engages in planting and selling of Chinese medicinal materials; processing … Read more
Lanzhou Foci Pharmaceutical Co Ltd (002644) - Net Assets
Latest net assets as of September 2025: CN¥1.85 Billion CNY
Based on the latest financial reports, Lanzhou Foci Pharmaceutical Co Ltd (002644) has net assets worth CN¥1.85 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.52 Billion) and total liabilities (CN¥678.01 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.85 Billion |
| % of Total Assets | 73.14% |
| Annual Growth Rate | 14.01% |
| 5-Year Change | 14.36% |
| 10-Year Change | 47.12% |
| Growth Volatility | 25.82 |
Lanzhou Foci Pharmaceutical Co Ltd - Net Assets Trend (2007–2024)
This chart illustrates how Lanzhou Foci Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Lanzhou Foci Pharmaceutical Co Ltd (2007–2024)
The table below shows the annual net assets of Lanzhou Foci Pharmaceutical Co Ltd from 2007 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.81 Billion | +2.63% |
| 2023-12-31 | CN¥1.77 Billion | +1.99% |
| 2022-12-31 | CN¥1.73 Billion | +6.54% |
| 2021-12-31 | CN¥1.63 Billion | +2.55% |
| 2020-12-31 | CN¥1.59 Billion | +5.32% |
| 2019-12-31 | CN¥1.51 Billion | +4.62% |
| 2018-12-31 | CN¥1.44 Billion | +5.98% |
| 2017-12-31 | CN¥1.36 Billion | +5.31% |
| 2016-12-31 | CN¥1.29 Billion | +4.61% |
| 2015-12-31 | CN¥1.23 Billion | +67.79% |
| 2014-12-31 | CN¥735.22 Million | +4.53% |
| 2013-12-31 | CN¥703.37 Million | +4.12% |
| 2012-12-31 | CN¥675.53 Million | +4.24% |
| 2011-12-31 | CN¥648.08 Million | +98.52% |
| 2010-12-31 | CN¥326.46 Million | +29.06% |
| 2009-12-31 | CN¥252.96 Million | +16.67% |
| 2008-12-31 | CN¥216.81 Million | +11.07% |
| 2007-12-31 | CN¥195.20 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Lanzhou Foci Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 668.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥814.87 Million | 45.53% |
| Common Stock | CN¥510.66 Million | 28.53% |
| Other Comprehensive Income | CN¥164.25 Million | 9.18% |
| Other Components | CN¥300.12 Million | 16.77% |
| Total Equity | CN¥1.79 Billion | 100.00% |
Lanzhou Foci Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Lanzhou Foci Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Alico Inc
NASDAQ:ALCO
|
$229.15 Million |
|
Hefei Gocom Information Technology Co Ltd
SHG:688367
|
$229.16 Million |
|
WIRTUALNA POL.BC ZY -05
F:9DE
|
$229.16 Million |
|
Medistim ASA
OL:MEDI
|
$229.18 Million |
|
JNTC Co. Ltd
KQ:204270
|
$229.09 Million |
|
Shanxi Yongdong Chemistry Industry Co Ltd
SHE:002753
|
$228.99 Million |
|
Jiangsu Xinning Modern Logist
SHE:300013
|
$228.96 Million |
|
METALL ZUG AG Part. Cert.
LSE:0QLX
|
$228.96 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Lanzhou Foci Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,745,370,807 to 1,789,888,294, a change of 44,517,487 (2.6%).
- Net income of 60,069,813 contributed positively to equity growth.
- Dividend payments of 15,955,346 reduced retained earnings.
- Other comprehensive income increased equity by 163,035,357.
- Other factors decreased equity by 162,632,337.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥60.07 Million | +3.36% |
| Dividends Paid | CN¥15.96 Million | -0.89% |
| Other Comprehensive Income | CN¥163.04 Million | +9.11% |
| Other Changes | CN¥-162.63 Million | -9.09% |
| Total Change | CN¥- | 2.55% |
Book Value vs Market Value Analysis
This analysis compares Lanzhou Foci Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.53x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 15.35x to 2.53x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-12-31 | CN¥0.58 | CN¥8.88 | x |
| 2008-12-31 | CN¥0.66 | CN¥8.88 | x |
| 2009-12-31 | CN¥0.76 | CN¥8.88 | x |
| 2010-12-31 | CN¥0.98 | CN¥8.88 | x |
| 2011-12-31 | CN¥1.94 | CN¥8.88 | x |
| 2012-12-31 | CN¥1.52 | CN¥8.88 | x |
| 2013-12-31 | CN¥1.58 | CN¥8.88 | x |
| 2014-12-31 | CN¥2.05 | CN¥8.88 | x |
| 2015-12-31 | CN¥2.61 | CN¥8.88 | x |
| 2016-12-31 | CN¥2.53 | CN¥8.88 | x |
| 2017-12-31 | CN¥2.66 | CN¥8.88 | x |
| 2018-12-31 | CN¥2.82 | CN¥8.88 | x |
| 2019-12-31 | CN¥2.95 | CN¥8.88 | x |
| 2020-12-31 | CN¥3.10 | CN¥8.88 | x |
| 2021-12-31 | CN¥3.16 | CN¥8.88 | x |
| 2022-12-31 | CN¥3.36 | CN¥8.88 | x |
| 2023-12-31 | CN¥3.42 | CN¥8.88 | x |
| 2024-12-31 | CN¥3.50 | CN¥8.88 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Lanzhou Foci Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.36%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 6.13%
- • Asset Turnover: 0.40x
- • Equity Multiplier: 1.38x
- Recent ROE (3.36%) is below the historical average (6.67%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | 11.94% | 13.13% | 0.49x | 1.84x | CN¥3.79 Million |
| 2008 | 9.97% | 9.87% | 0.55x | 1.85x | CN¥-72.05K |
| 2009 | 14.29% | 15.57% | 0.55x | 1.67x | CN¥10.85 Million |
| 2010 | 15.70% | 19.53% | 0.58x | 1.40x | CN¥18.60 Million |
| 2011 | 4.95% | 11.82% | 0.33x | 1.28x | CN¥-32.75 Million |
| 2012 | 4.49% | 11.40% | 0.32x | 1.22x | CN¥-37.20 Million |
| 2013 | 4.35% | 10.50% | 0.32x | 1.28x | CN¥-39.74 Million |
| 2014 | 4.71% | 8.68% | 0.38x | 1.42x | CN¥-38.87 Million |
| 2015 | 3.48% | 13.11% | 0.24x | 1.10x | CN¥-80.42 Million |
| 2016 | 4.72% | 16.77% | 0.18x | 1.58x | CN¥-68.13 Million |
| 2017 | 5.45% | 14.78% | 0.21x | 1.73x | CN¥-61.82 Million |
| 2018 | 5.06% | 13.39% | 0.22x | 1.75x | CN¥-71.12 Million |
| 2019 | 4.73% | 11.31% | 0.26x | 1.60x | CN¥-79.38 Million |
| 2020 | 6.83% | 16.17% | 0.28x | 1.51x | CN¥-50.19 Million |
| 2021 | 5.78% | 11.41% | 0.35x | 1.46x | CN¥-68.20 Million |
| 2022 | 6.33% | 10.66% | 0.39x | 1.51x | CN¥-62.88 Million |
| 2023 | 3.85% | 5.78% | 0.46x | 1.45x | CN¥-107.35 Million |
| 2024 | 3.36% | 6.13% | 0.40x | 1.38x | CN¥-118.92 Million |
Industry Comparison
This section compares Lanzhou Foci Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $2,123,990,643
- Average return on equity (ROE) among peers: -0.22%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Lanzhou Foci Pharmaceutical Co Ltd (002644) | CN¥1.85 Billion | 11.94% | 0.37x | $229.10 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $6.47 Billion | 9.88% | 3.77x | $616.08 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.18 Billion | 2.74% | 0.95x | $320.56 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $10.33 Billion | 15.07% | 0.27x | $3.03 Billion |
| Wedge Industrial Co Ltd (000534) | $298.72 Million | 1.96% | 0.38x | $1.77 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $35.11 Million | 18.13% | 0.80x | $5.62 Billion |
| Hainan Haiyao Co Ltd (000566) | $353.98 Million | -9.58% | 0.80x | $702.18 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $269.51 Million | -61.02% | 1.05x | $317.08 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $927.49 Million | 2.65% | 1.38x | $425.60 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $1.11 Billion | 7.32% | 0.29x | $2.05 Billion |
| Renhe Pharmacy Co Ltd (000650) | $261.49 Million | 10.60% | 0.82x | $777.45 Million |